Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis

NCT04442269 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04442269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2020
Completion date
February 9, 2024
Enrollment
62 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

allergic bronchopulmonary aspergillosis